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dent, unhealthy, alcohol use (identified by screening)
who are randomized to receive brief counseling subse-
quently report drinking less than those randomized to
control groups [1-4]. Most studies do not have biological
confirmation, and those that do generally do not find ef-
fects on such outcomes, nor on any hard outcomes
(though some do [4]). The lack of evidence for effects
on these outcomes raises the possibility that alcohol
screening and brief intervention efficacy remains un-
known, since the modest effects on drinking could easily
be due to social desirability bias [5] (i.e., patients are told
they are in a study of counseling to reduce their drink-
ing, they are randomly assigned to brief counseling with
that goal, and then they are asked whether they reduced
their drinking, so they may therefore report less drinking
to please the interviewer; this would be expected to
occur more often in an intervention than in a control
group). This possibility should be resolved by further
study (i.e., randomized trials with biological outcomes).
But if we take the positive trial findings as being valid—
and many scientists and practitioners have [6]—the ques-
tion is whether they represent efficacy or effectiveness.
This question is important because if alcohol screening
and brief intervention (ASBI) has efficacy, the next steps
would be to determine how to implement it and retain
effectiveness in real-world practice. But if the evidenceCorrespondence: rsaitz@bu.edu
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unless otherwise stated.supports effectiveness, little further study would be
needed, and efforts would turn to dissemination and
implementation.
In Addiction Science & Clinical Practice, Heather [7]
makes the case that extant trials suggest that ASBI is ef-
fective. His case relies largely on two arguments. First
and foremost, Heather observes that based on an effective-
ness scale, randomized trials of ASBI can be characterized
mainly as effectiveness studies. He does concede that the
scale may have minor, and mainly methodological, limita-
tions. But I believe the scale to be highly flawed for evaluat-
ing whether a trial of a preventive service like ASBI is an
effectiveness or an efficacy study.
The scale as reported in Kaner et al. [4] emphasizes
patients, practitioners, and intervention content. Such a
scale could be useful for describing studies of lengthy
interventions delivered by specialists developed for se-
lected patients. Then, when such an intervention is
somehow adapted for use in less selected patients to be
delivered by generalists in general care settings, the trial
will be appropriately characterized as an effectiveness
study. But this conceptual approach does not apply to
ASBI. ASBI was designed and developed as a brief ser-
vice for all patients (i.e., unselected) to be delivered by
practitioners who are not highly specialized, in general
care settings. So even the most tightly controlled efficacy
study would score as an effectiveness study on the scale.
More specifically, ASBI is designed for all primary care
patients and starts with universal screening. It would not
make sense to test a universal preventive service in se-
lected or referred patients in an alcohol specialist clinic. If
one did so, it would no longer be ASBI. By definition, any
study of ASBI will score as effectiveness on “patients ands is an Open Access article distributed under the terms of the Creative
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“brief” intervention will score high for effectiveness on
“intervention content” because the timing could fit with
general practice (e.g., 15 minutes). To be characterized as
an efficacy study, the intervention would need to be much
longer, but then of course it would no longer be brief
intervention; it would be something else. ASBI based on
personalized feedback and/or motivational interviewing is
by design therapeutically flexible; so again, it will score
high for effectiveness (by definition) since flexibility is
characteristic of ASBI.
Thus, because of the nature of ASBI, just about any
study of it would be characterized as an effectiveness
study by the scale, and the only variability might be
whether the ASBI or some component of it was per-
formed by research staff, and whether it was monitored
or supported by research staff. On these features, many
ASBI studies in fact do look like efficacy studies. Practi-
tioner training was usually implemented and orchestrated
by researchers championing the effort. ASBI would not
have occurred in the studies were it not for substantial
researcher involvement. For example, researchers often per-
formed the screening and provided the results to those con-
ducting the BI. Investigators have been generally available
to support ongoing ASBI implementation in these studies.
And studies often monitored and assured fidelity of the BI.
Although ASBI studies often begin with universal screen-
ing, many patients with unhealthy drinking are excluded
for clinical and research reasons, such as drinking too
little or too much, having alcohol dependence [8], hav-
ing significant psychiatric or medical comorbidity, or
for research reasons, such as being difficult to follow
up, in addition to the fact that many simply choose not
to participate in the trials.
The fact that ASBI trials have been conducted in pri-
mary care, often by primary care practitioners as inter-
ventionists in initially unselected patients, should not
lead us to conclude that they are effectiveness trials,
even if a scale would count them as such for those rea-
sons. They are still studies that were controlled by re-
searchers much more than usual interventions would be
in routine clinical practice.
Evidence for the case that these have been largely effi-
cacy studies is that two of the studies designed as effect-
iveness studies found no intervention effects [9-11].
They differed primarily from the rest of the ASBI trial
literature in that the researchers had less control over
intervention implementation (though even in the SIPS
trial [9] when practitioners wouldn’t do the BI, re-
searchers stepped in), fidelity, support, monitoring, and
patient selection, yet they were similar to the rest of the
literature in that they took place in primary care settings
and used a flexible intervention delivered by real practi-
tioners. These two studies clearly were effectiveness studies,very different from most other ASBI trials, yet they would
score similarly on the effectiveness scale.
The second argument made by Heather [7] and Flay [12]
is that in treatment effectiveness studies, the available inter-
vention is optimized but acceptability could be variable,
whereas the latter would be optimized in efficacy studies.
But for ASBI, the distinction between these two (availability
and acceptability) is minimal. Most ASBI intervention
studies make BI “available in uniform fashion, within
standardized contexts/setting, to a specified target
group” (characteristic of efficacy studies according to
Heather [7]). The distinguishing feature for Heather is
whether or not it is delivered in a “manner acceptable
to them [the patients]”. But once one has a patient who
has agreed to be in a trial of an alcohol BI in primary
care, it is likely that it will be acceptable (they will par-
ticipate in the brief counseling), particularly if the
intervention is flexible and provided on the spot, which
ASBI usually is by design. ASBI as a service conceptu-
alized and designed for primary care is brief, delivered
in primary care at the time of the visit.
In sum, because of the very nature of the intervention,
the only way to test ASBI is in studies that would have
the characteristics of effectiveness studies according to
the scale used by Kaner et al. [4]. I suggest that despite
this, there are meaningful distinctions that should be
made in characterizing these studies on the spectrum of
efficacy versus effectiveness that are not captured by the
scale for this preventive intervention. They are distinc-
tions that primary care clinicians would instantly
recognize—e.g., having special staff for training and im-
plementation who are not usually in their practice taking
steps to monitor and support fidelity, and having pa-
tients identified by research staff who prompt an inter-
vention. Just because the study is completed in primary
care and the intervention designed for that setting is
(by definition) acceptable, does not make it an effect-
iveness study. Or, if we wish to say that based on the
scale, they are effectiveness studies, then I suggest that
for ASBI the distinction between effectiveness and effi-
cacy studies is not meaningful. We then need another
kind of study—a real-world [12] “does it work on a wet
Wednesday in Wigan” study, which most ASBI studies are
not.
If the current literature were truly replete with real-
world ASBI effectiveness studies, then we would likely
see ASBI being widely disseminated (it is not), and im-
plemented successfully. Yet in one of the only large
health systems with widespread ASBI implementation,
the benefit of ASBI is undetectable [13]. Regardless of
whether we agree to call ASBI studies effectiveness re-
search (you say tomāto, I say tomăto), the bottom line is
that the current literature is not very informative about
whether ASBI works under real-world conditions.
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